SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Advaxis, Inc. Warrants (ADXSW)

ADXSW RSS Feed
Add ADXSW Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 9/1/2016 1:59:43 PM - Followers: 1 - Board type: Free - Posts Today: 0
Advaxis, Inc.

305 College Road East
Princeton, NJ 08540
United States
609-452-9813

http://www.advaxis.com

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac (ADXS-HPV), an Lm-LLO immunotherapy product candidate, which completed its Phase II study used for the treatment of human papilloma virus (HPV) associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen (PSA) antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has clinical trial collaboration agreements with Merck & Co., Inc. for the Phase I/II dose-escalation and safety study of ADXS31-142; MedImmune, LLC to initiate a Phase I/II clinical study in the United States to evaluate the safety and efficacy of MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV; and Incyte Corporation for the development and analysis of a combination therapy for the treatment of cervical cancer. The company also has a licensing agreement with Global BioPharma, Inc.; development and commercialization agreement with Especificos Stendhal SA de CV.; and collaboration agreement with Amgen Inc. for the development and commercialization of Advaxis' ADXS-NEO, a preclinical investigational cancer immunotherapy treatment that activates patient's immune system to respond against mutations and neoepitopes. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ADXSW
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ADXSW News: Advaxis Announces Closing of Public Offering of Common Stock and Warrants 10/22/2013 12:46:00 PM
ADXSW News: Advaxis Announces Full Exercise of Underwriters’ Over-Allotment Option 10/18/2013 01:45:00 PM
PostSubject
#9   I look at it like buying shares..the premiums bill_y 09/01/16 01:59:43 PM
#8   Thanks. It is something I have never even jaxstraw 09/01/16 07:03:00 AM
#7   One warrant plus 5.00 gets you 1 share bill_y 08/31/16 02:12:15 PM
#3   Just found this board. jaxstraw 08/31/16 12:42:25 PM
#2   ADXSW bullish 7.65 stocktrademan 08/26/16 10:49:52 AM
#1   ADXSW bullish 9.72 stocktrademan 08/22/16 11:42:37 AM
PostSubject